Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03514121 · ClinicalTrials.gov registry record · Early Phase 1
FPA150 in Patients With Advanced Solid Tumors
A Early Phase 1 study, sponsored by Five Prime Therapeutics.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 95
- Enrollment target
NCT03514121 is a Early Phase 1 study that was terminated before completion, run by Five Prime Therapeutics. The registered enrollment target is 95 participants.
The verdict
NCT03514121, a Early Phase 1 study, was terminated before completion, sponsored by Five Prime Therapeutics.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 95 participants
- Enrollment target
Study Summary
This is a multi-center study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of FPA150, an anti-B7H4 antibody alone or in combination with pembrolizumab an anti-PD1 antibody in patients with advanced solid tumors. The Phase 1a, open-label, cohort will identify a recommended dose of FPA150 to use for Phase 1a Combination (FPA150 and Pembrolizumab) Safety Lead-in and for Phase 1b monotherapy cohorts.
Interventions
- BIOLOGICAL Pembrolizumab
- BIOLOGICAL FPA150
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 2018-03-27 |
| Est. Completion | 2021-04-21 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03514121
The ClinicalTrials.gov registry entry for NCT03514121 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 95 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Five Prime Therapeutics, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT03514121 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03514121 about?
NCT03514121 is a clinical study titled "FPA150 in Patients With Advanced Solid Tumors". This is a multi-center study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of FPA150, an anti-B7H4 antibody alone or in combination with pembrolizumab an anti-PD1 antibody in patients with advanced solid tumors. The Phase 1a, open-label, ...
What is the current status of trial NCT03514121?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 95 participants. The study started on 2018-03-27. Estimated completion is 2021-04-21.
What interventions are being tested in trial NCT03514121?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), FPA150 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03514121?
This trial is sponsored by Five Prime Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.